Having Dr. Jorgensen guiding Brilacidin forward t

Having Dr. Jorgensen guiding Brilacidin forward through trials is a huge asset to the company. He can speak with confidence about Brilacidin, as he was formerly the CMO at PYMX and has extensive experience and expertise in the field. He has a very impressive bio, and some very interesting connections.

Here is a good summary on Dr. Jorgensen from a past PYMX PR:

RADNOR, Pa., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Polymedix, Inc. (OTCBBYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening acute cardiovascular disorders and infectious diseases, has appointed Daniel M. Jorgensen as Senior Vice President, Clinical Development and Chief Medical Officer. In this role, Dr. Jorgensen will be responsible for implementing PolyMedix's global clinical strategy.

"We are thrilled to welcome Dan as the latest addition to our management team," said Nicholas Landekic, President and CEO of PolyMedix. "He is an accomplished clinician and drug developer who brings to PolyMedix comprehensive research, development and commercialization experience in infectious disease, and a proven track record of innovation with successful antibiotic compounds. Dr. Jorgensen's expertise with antibiotic clinical trials, combined with his knowledge of regulatory pathways for antibiotics and his experience preparing multiple NDA submissions, will be particularly instrumental for the continued clinical development of our novel defensin-mimetic antibiotic PMX-30063. We are honored to have someone with Dan's capabilities and experiences join our company."

Dr. Jorgensen has had an accomplished career at both large pharmaceutical and earlier stage biotechnology companies. He has held senior leadership positions in the Global Research and Development Division at Pfizer, Inc. Most notably, Dr. Jorgensen led the Zmax single-dose azithromycin clinical development program, the dalbavancin (second generation glycolipopeptide) medical development team, and Pfizer's first vaccine development group. Prior to joining PolyMedix, he served as Vice President, Clinical Research at AMAG Pharmaceuticals, where he oversaw ten global clinical trials across multiple medical areas. During his 25-year career in health care, Dr. Jorgensen has also worked at Aventis Pasteur, at the Centers for Disease Control and Prevention (CDC) as an Epidemic Intelligence Service Officer, and as Montana's State Medical Officer. Dr. Jorgensen received his BS degree from Yale, his MD from the University of Wisconsin, his MPH from the University of Washington, and his MBA from Yale. He is board-certified in three medical areas: pediatrics, infectious diseases, and preventive medicine.

Sounds damn good to me, I don't think someone of his caliber comes on board at CTIX without an expectation of success for Brilacidin.